We are live on
!
Find out more
ACM
Aisling Capital Management Portfolio holdings
AUM
$472M
1-Year Est. Return
106.83%
This Fund
S&P 500
This Quarter
Est. Return
+12.93%
1 Year Est. Return
+106.83%
3 Year Est. Return
+792.82%
5 Year Est. Return
+1,009.42%
10 Year Est. Return
–
AUM
$472M
AUM Growth
-$4.67M
(-0.98%)
Cap. Flow
-$33.3M
Cap. Flow
% of AUM
-7.06%
Top 10 Holdings %
Top 10 Hldgs %
98.96%
Holding
14
New
1
Increased
–
Reduced
1
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
vTv Therapeutics
VTVT
|
+$1.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BridgeBio Pharma
BBIO
|
+$35M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
PC
LSA
AWA
PWM
CAP
SWRP
CFLC
WCM
Aisling Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Aisling Capital Management held 14 positions worth $472M, down 0.98% from $476M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Aisling Capital Management withdrew a net $33.3M in Q2 2026, reducing 1 holding. Its largest reduction was BridgeBio Pharma, cutting an estimated $35M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Aisling Capital Management opened a new position in vTv Therapeutics worth $1.88M.
- Aisling Capital Management's largest Q2 2026 buy was vTv Therapeutics: 50,000 shares worth $1.88M.
- Aisling Capital Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $35M.
- Aisling Capital Management's ten largest holdings make up 99% of its $472M portfolio in Q2 2026.
- Aisling Capital Management opened 1 new position and closed 0 in Q2 2026.
- Aisling Capital Management's portfolio value fell 0.98% quarter-over-quarter to $472M.
Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.